DUBLIN, March 8, 2022 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that
pre-clinical data on JZP815, an investigational, next-generation
pan-RAF kinase inhibitor, will be presented as a poster at the
American Association for Cancer Research (AACR) 2022 Annual
Meeting from April 8-13,
2022.
"Together with our pre-clinical collaboration partner, Redx
Pharma, we look forward to presenting at AACR our first
pre-clinical data on JZP815, which demonstrated that it selectively
and potently inhibits mutant A, B and CRAF kinases, and
demonstrated anti-tumor activity in RAS- and RAF-mutant xenograft
models," said Rob Iannone, M.D.,
M.S.C.E., executive vice president, global head of research and
development of Jazz Pharmaceuticals. "The pan-RAF inhibitor program
is part of a novel class of next generation precision oncology
therapies that has the potential to benefit cancer patients with
high unmet needs in multiple different solid tumors. We look
forward to progressing JZP815 to the clinic to further evaluate the
benefit it may have for appropriate patients."
The Jazz presentation abstract – titled, "JZP815, a potent and
selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS
mutant tumor pre-clinical models" – and the AACR 2022 Annual
Meeting details are available here.
Activation of the mitogen-activated protein kinase (MAPK)
pathway by oncogenic mutations in RAS and RAF is a frequent driver
of cancer. Targeting specific components of the pathway can be a
precise and rational route to deliver benefits to cancer patients
with high unmet needs. The RAF kinase proteins (ARAF, BRAF, CRAF)
are core pathway components that mediate MAPK signaling. Mutations
in these critical signaling proteins leads to constitutive
activation of the MAPK pathway and tumor growth.
JZP815 is an investigational, pre-clinical stage,
next-generation pan-RAF kinase inhibitor that was discovered and
developed using state-of-the-art screening methodologies and
medicinal chemistry. JZP815 is not currently approved for use
anywhere in the world.
Jazz acquired JZP815 from Redx Pharma, and the two companies are
collaborating on this pre-clinical research. Jazz plans to submit
an IND for JZP815 this year. JZP815 is part of Jazz's growing
early-stage R&D pipeline focused on precision oncology in solid
tumors.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals
plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose
purpose is to innovate to transform the lives of patients and their
families. We are dedicated to developing life-changing medicines
for people with serious diseases—often with limited or no
therapeutic options. We have a diverse portfolio of marketed
medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic
areas, we are identifying new options for patients by actively
exploring small molecules and biologics, and through innovative
delivery technologies and cannabinoid science. Jazz is
headquartered in Dublin, Ireland
and has employees around the globe, serving patients in nearly 75
countries. For more information, please visit
www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements, including,
but not limited to, statements related to Jazz Pharmaceuticals'
belief in the potential of JZP815 to provide a potentially new
therapeutic option for multiple solid tumor types; progressing
JZP815 to the clinic and other statements that are not historical
facts. These forward-looking statements are based on Jazz
Pharmaceuticals' current plans, objectives, estimates, expectations
and intentions and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, effectively registering JZP815 with
FDA and initiating clinical trials; launching and commercializing
new products; obtaining and maintaining adequate coverage and
reimbursement for the company's products; delays or problems in the
supply or manufacture of the company's products; and other risks
and uncertainties affecting the company, including those described
from time to time under the caption "Risk Factors" and elsewhere in
Jazz Pharmaceuticals' Securities and Exchange Commission filings
and reports (Commission File No. 001-33500), including Jazz
Pharmaceuticals' Annual Report on Form 10-K for the year ended
December 31, 2021 and future filings
and reports by Jazz Pharmaceuticals. Other risks and uncertainties
of which Jazz Pharmaceuticals is not currently aware may also
affect Jazz Pharmaceuticals' forward-looking statements and may
cause actual results and the timing of events to differ materially
from those anticipated. The forward-looking statements herein are
made only as of the date hereof or as of the dates indicated in the
forward-looking statements, even if they are subsequently made
available by Jazz Pharmaceuticals on its website or otherwise. Jazz
Pharmaceuticals undertakes no obligation to update or supplement
any forward-looking statements to reflect actual results, new
information, future events, changes in its expectations or other
circumstances that exist after the date as of which the
forward-looking statements were made.
Media Contact:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Investors:
Andrea N.
Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg